Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Low-dose fish oil supplementation not cardioprotective

13 Sep 2020

Taking less than two 1-g capsules of omega-3 does little to improve cardiovascular disease (CVD) outcomes, and it is likely to remain ineffective in future research, according to a meta-analysis.

Researchers performed a systematic review of double-blind randomized clinical trials assessing omega-3 supplementation over ≥1 year of follow-up. They searched multiple online databases and identified 17 studies for inclusion in the meta-analysis.

The total population consisted of 83,617 individuals. There were reports of 7,227 deaths, 3,830 cardiac deaths, 960 sudden deaths, 2,483 myocardial infarctions (MIs), and 1,704 strokes. Trials were published as far back as 1995, and 88 percent had been conducted during the period where statins were routinely recommended for CVD risk modification (1998 onwards).

Mean omega-3 dose was 1.64 g/day (0.96 g/day eicosapentaenoic acid, 0.59 g/day docosahexaenoic acid). Pooled data revealed that supplementation with ≤1 capsule/day was not associated with any outcome under study. Boundaries for futility were crossed for all-cause mortality and cardiac death.

However, supplementation with two capsules/day led to a marked reduction in cardiac death (n=3; relative risk [RR], 0.55, 95 percent confidence interval [CI], 0.33–0.90; I2, 0 percent), as did intake of at least three capsules/day (n=3; RR 0.82, 95 percent CI, 0.68–0.99; I2, 0 percent). The latter also showed a protective association with sudden death (n=1; RR, 0.70, 95 percent CI, 0.51–0.97) and stroke (n=2; RR, 0.74, 95 percent CI, 0.57–0.95; I2, 0 percent).

In light of the findings, omega-3 supplements should be considered as distinct interventions based on the administered doses and ratios, according to the researchers, adding that supplementation at doses of ≤1 capsule/day is unlikely to provide any real benefits in CVD prevention. For higher doses, more studies are needed to validate their protective effect.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.